| Evaluation of the Outcome after Transarterial Chemoembolization; Refinement of Barcelona Clinic Liver Cancer Stage-B from Eastern Point of View |
|
Namiki Izumi |
|
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan |
|
|
| Abstract |
|
Transarterial chemoembolization (TACE) is recommended as the first line treatment option
for the patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma
(HCC), however, treatment strategy and evaluation of effects after TACE has not been fully
established. Recently, sub-stage of BCLC stage B has been proposed and validated, but it
should be validated including a large number of the patients and its refinement should be
discussed. We have validated the sub-stage of BCLC stage B (B1-B4) by comparing overall
survival after TACE, and there was no statistically significant difference in overall survival
after TACE between B1 and B2. After excluding the patients with Child-Pugh point 7 from B1,
the overall survival was significantly better than that of B2. Therefore, up-to-seven criteria is
shown to be a reliable tool for the treatment strategy in the patients with intermediate stage
of HCC. Refinement of sub-stage of BCLC stage B has been proposed by some other institutes,
and it is important to establish novel treatment strategy for the patients with BCLC stage B
after TACE to improve the prognosis of the patients after TACE, and to define the best timing
for conversion to sorafenib or liver transplantation should be discussed. (J Liver Cancer
2016;16:7-11) |
| Key Words:
Hepatocellular carcinoma; Barcelona Clinic Liver Cancer stage; Subclassification; Chemoembolization |
|
NULL |
|
PDF Links
Full text via DOI
Download Citation
CrossRef TDM
E-Mail
